A Meta‐Analysis of Prior Corticosteroid Use and Fracture Risk

By J. Kanis, H. Johansson, A. Odén, O. Johnell, C. D. de Laet, L. Melton, A. Tenenhouse, J. Reeve, A. Silman, H. Pols and 3 more. Journal of Bone and Mineral Research, 2004

834 citations recorded by the source corpus.

Subfields: Orthopedics and Sports Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/afb5b36405456abd566678698ed9d44c470e11e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Orthopedics and Sports Medicine

Citations in the corpus

FRAX™ and the assessment of fracture probability in men and women from the UK (2008, background): “Rheumatoid arthritis carries a fracture risk over and above that provided by BMD [11].”
Glucocorticoid-induced osteoporosis (2015, neutral): “…for treatment in patients with GCs: the same diagnostic criterion as in postmenopausal women has been suggested (T ≤− 2.5), 50 but a higher threshold (ie, T ≤− 1.5) has been proposed for intervention, 46 because bone loss can be 10% or more in some individuals over the ﬁ rst year of GC use.”
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary (2010, background): “5 mg daily).(24) The presence of either risk factor raises the individual’s risk to the next risk category (i.”
Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK (2008, background): “for 3 months or more) of oral glucocorticoids [17], rheumatoid arthritis [17], current cigarette smoking [18] and high alcohol consumption (3 or more units/daily) [19].”
Assessment of fracture risk (2005, background): “The fracture risk conferred by the use of corticosteroids is, however, not solely dependent upon bone loss, and BMD independent risks have been identified (see Table 6) [37].”
European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008, methodology): “The risk factors that are used for clinical assessment with FRAX are summarised in Table 5 [8, 38, 60–65].”
Trabecular Bone Score: A Noninvasive Analytical Method Based Upon the DXA Image (2014, background): “In cases of long‐term glucocorticoid (GC) therapy, for example, the increase in fracture risk is largely independent of BMD by DXA,((73)) which could be related to alterations in bone microstructure as described by histomorphometric parameters.”
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy (2013, background): “Kanis and colleagues examined 42,500 subjects from seven prospectively studied cohorts followed for 176,000 patient-years and found that prior and current use of corticosteroids increased fracture risk in both adult men and women, regardless of BMD and prior fracture history [15].”
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women (2007, neutral): “These comprised a parental history of hip fracture [11], exposure to systemic glucocorticoids [12], a prior history of fragility fracture [13], current smoking [18], high intake of alcohol (>2 units daily on average) [16] and the presence of rheumatoid arthritis [12].”
UK clinical guideline for the prevention and treatment of osteoporosis (2017, background): “use of glucocorticoids is, however, not solely dependent upon bone loss and BMD-independent risks have been identified [36, 37] (Evidence level 1a).”